Lp-PLA2 Blood Test (Lipoprotein-Associated Phospholipase A2)

The Lp-PLA2 Blood Test measures lipoprotein-associated phospholipase A2, an enzyme produced by inflammatory cells within the arterial wall. Unlike traditional cholesterol markers, which indicate the amount of lipid circulating in the blood, Lp-PLA2 reflects active inflammation inside blood vessels and is increasingly recognised as an independent risk marker for cardiovascular events. This test is suitable for adults who wish to gain a deeper understanding of their cardiovascular risk, particularly those with a family history of heart disease, borderline or normal cholesterol results, or a personal history of vascular conditions. It may also be useful for individuals who have already had a cardiovascular event and want further insight into their ongoing inflammatory burden. A simple blood sample is all that is required, collected by a trained phlebotomist.

Biomarkers included

• Lipoprotein-associated phospholipase A2 (Lp-PLA2): an enzyme that circulates bound mainly to low-density lipoprotein and is released by inflammatory cells within atherosclerotic plaques. Elevated levels indicate increased vascular inflammation and have been associated with a higher risk of coronary heart disease and ischaemic stroke, independent of traditional risk factors such as cholesterol, blood pressure, and smoking status.

Why it matters

Standard lipid profiles tell only part of the cardiovascular story. Many people with normal cholesterol still experience heart attacks and strokes, and inflammation within the artery wall is now understood to play a central role in plaque formation and instability. Measuring Lp-PLA2 provides a direct window into this inflammatory process, helping to identify individuals who may benefit from more focused risk reduction strategies. It can be used alongside conventional lipid testing to build a more complete picture of cardiovascular health, supporting informed discussions with your doctor about lifestyle measures, monitoring, and whether further assessment or treatment is appropriate.